The Effect of Exercise on Cardiometabolic Risk Factors in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.

BACKGROUND: Polycystic Ovary Syndrome (PCOS), a common endocrine disorder in women of reproductive age, increases the risk for cardiometabolic morbidity. While regular exercise is effective in reducing cardiometabolic risk, women with PCOS may experience condition-specific barriers to exercise thereby limiting its efficacy. AIM: To determine the effect of exercise on cardiometabolic risk factors in women with PCOS. METHODS: Five databases (Cochrane, EMBASE, Medline, Scopus and SPORTDiscus) were searched up to December of 2021. Eligible studies included: a randomised controlled design; participants with a diagnosis of PCOS; aerobic and/or resistance exercise intervention lasting ≥4 weeks; cardiometabolic outcomes. Meta-analyses were performed to determine the effect of exercise versus non-exercising control on cardiometabolic outcomes. RESULTS: Of the 4517 studies screened, 18 studies were analysed involving 593 participants. When compared with control, exercise significantly improved cardiorespiratory fitness (weighted mean difference {WMD} = 4.00 mL/kg/min, 95% CI: 2.61 to 5.40, p < 0.001) and waist circumference (WMD = -1.48 cm, 95% CI: -2.35 to -0.62, p = 0.001). Systolic blood pressure, fasting blood glucose, insulin resistance, and lipid profiles remained unchanged. CONCLUSIONS: Regular exercise may improve cardiorespiratory fitness and waist circumference in women with PCOS. Further large-scale studies are required to determine whether exercise interventions improve various biochemical and anthropometric parameters in women with PCOS and more severe cardiometabolic abnormalities.

Prognostic Differences of RAS Mutations: Results from the South Australian Metastatic Colorectal Registry.

BACKGROUND: Effective targeting of RAS mutations has proven elusive until recently. Novel agents directly targeting KRAS G12C have shown promise in early-phase clinical trials that included patients with metastatic colorectal cancer. Prior reports have suggested that G12C mutation may be predictive of poor outcome. OBJECTIVE: Assessment of the specific characteristics and prognostic implications of individual RAS mutation subtypes in patients with metastatic colorectal cancer. PATIENTS AND METHODS: Retrospective review of individual RAS mutation types from the South Australian Metastatic Colorectal Registry between 2006 and 2020. RESULTS: Of the 5165 patients entered onto the registry, 2305 (45%) had RAS mutation results available. 772 (33%) had a RAS mutation. The nature of the RAS mutation was available in 668 (87% of those with RAS mutation). Rare mutations (outside codons 12 and 13) made up 12.6% of the total. There were numerical differences in survival between the specific RAS mutation subgroups, with the longest median overall survival (30 months) observed in those with G12S mutations. However, there was no statistical difference in survival when comparing the various RAS mutations, including the comparison of G12C to G12S (p = 0.38). Patients with cancer harbouring rare RAS mutations had a median survival of 30 months. CONCLUSIONS: Whilst the G12S mutation was associated with the longest survival numerically, the observed survival for patients with the most common RAS mutations (G12C, G12V, G12A, G12D and G13D) did not significantly differ.

The solvation of Cu2+ with gas-phase clusters of water and ammonia.

A detailed study has been undertaken of the gas-phase chemistry of [Cu(H2O)N]2+ and [Cu(NH3)N]2+ complexes. Ion intensity distributions and fragmentation pathways (unimolecular and collision-induced) have been recorded for both complexes out as far as N=20. Unimolecular fragmentation is dominated by Coulomb explosion (separation into two single charged units) on the part of the smaller ions, but switches to neutral molecule loss for N>7. In contrast, collisional activation promotes extensive electron capture from the collision gas, with the appearance of particular singly charged fragment ions being sensitive to the size and composition of the precursor. The results show clear evidence of the unit [Cu(X)8]2+ being of special significance, and it is proposed that the hydrogen-bonded structure associated with this ion is responsible for stabilizing the dipositive charge on Cu2+ in aqueous solution.

Veganism and osteoporosis: a review of the current literature.

The purpose of this review is to examine the current literature regarding calcium and Vitamin D deficiencies in vegan diets and the possible relationship to low bone mineral density and incidence for fracture. Prominent databases were searched for original research publications providing data capable of answering these questions: (i) Do vegans have lower-than-recommended levels of calcium/Vitamin D? (ii) Do vegans have lower bone mineral density than their non-vegan counterparts? (iii) Are vegans at a greater risk for fractures than non-vegans? The findings gathered consistently support the hypothesis that vegans do have lower bone mineral density than their non-vegan counterparts. However, the evidence regarding calcium, Vitamin D and fracture incidence is inconclusive. More research is needed to definitively answer these questions and to address the effects of such deficiencies on the medical and socioeconomic aspects of life.

Opening the dialogue: Herbal supplementation and chemotherapy.

Presently, healthcare providers have little scientific evidence on which to base recommendations about use of herbal supplements with chemotherapy. Lack of product standardization and definitive knowledge about herb interaction with chemotherapy may expose patients with cancer to potentially serious side effects. Patients continue to use herbal supplements with their cancer treatments, often without informing their healthcare providers. Research currently is ongoing to study the effects of the concomitant administration of herbal supplements and chemotherapy.